Group 1 - The Hong Kong stock market saw a significant rise, with the Hang Seng Technology Index increasing by 3% and the Hang Seng Index up by over 2.1%, particularly in the healthcare sector [1] - The Hong Kong Innovative Drug ETF (159567) experienced a rise of over 4% during trading, with a turnover rate exceeding 20%. WuXi AppTec saw a peak increase of over 15%, currently up by 13.3%, along with other stocks like WuXi Biologics and Kanglongda-B rising over 5% [1] - The ETF attracted a capital inflow of 3.46 million yuan on March 17, with a latest circulation scale of 534 million yuan and a circulation share of 464 million, both reaching historical highs [1] Group 2 - Minsheng Securities highlighted the recovery of the biotech sector in Hong Kong, driven by improving fundamentals and supportive policies, focusing on high-quality assets in pharmaceutical consumption and innovation [2] - Zhongtai Securities suggested a shift in market style, recommending attention to performance-driven sectors, particularly in CRO & CDMO, upstream research, and specialty raw materials, anticipating a dual recovery in performance and valuation [2] - Everbright Securities analyzed three payment channels in the pharmaceutical industry, expressing optimism about policy support for innovative drugs and devices, expanding consumer demand, and the upward cycle of overseas sales [2]

Group 1 - The Hong Kong stock market showed positive momentum with the Hang Seng Index rising by 1.91% and the Hang Seng Tech Index increasing by 2.81% as of the morning of March 18 [1] - The Hong Kong Tech ETF (159751) experienced a gain of 3.28%, with a trading volume exceeding 55.88 million and a turnover rate of 11.8%, indicating active trading [1] - Notable gains were observed in component stocks, with WuXi AppTec rising over 13%, WuXi Biologics increasing by over 7%, and Alibaba, Kuaishou, and Bilibili each gaining over 4% [1] Group 2 - China AI Day, part of NVIDIA's GTC 2025 conference, will feature major domestic cloud and internet companies sharing advancements in large language models (LLM), multimodal large language models (MLLM), data science, and search promotion [1] - The event will include participation from companies such as ByteDance, Alibaba Cloud, Baidu, Ant Group, JD.com, Meituan, Kuaishou, and others, showcasing how they optimize AI performance and efficiency through hardware and software collaboration [1] Group 3 - Overall, external disturbances are stabilizing, and the spring market is expected to continue, driven by demand recovery and supply contraction leading to profit improvements and capital inflows [2] - The technology growth sector remains a primary focus, with a mid-term trend of confidence reassessment in Chinese assets expected to persist [2] - After a sustained upward trend in the Hong Kong stock market, the proportion of stocks above the 20-day moving average rose from 22.9% to a high of 90.4% on March 7, indicating a significant market breadth improvement [2]

| | 国泰君安证券 | | --- | --- | | | GUOTAI JUNAN SECURITIES | 目 录 | | 每日报告回放（2025-03-13 09:00——2025-03-14 15:00） 2 | | | --- | --- | --- | |  | 事件点评：《通胀降温或为暂时，仍需警惕"滞胀交易"》2025-03-13 | 2 | |  | A 股策略观察：《外资交易热度抬升，杠杆资金延续流入》2025-03-14 | 3 | |  | 行业更新：煤炭《下行风险释放，4 月有望进入上升通道》2025-03-14 | 3 | |  | 行业专题研究：计算机《DeepSeek 重构算力基建长期价值的认知》2025-03-14 | 4 | |  | 行业首次覆盖：化学制剂《抗肿瘤疗法持续迭代，国产新药迎来突破》2025-03-13 | 5 | |  | 行业日报/周报/双周报/月报：环保《首批 CCER 登记，全国碳市场加速完善》2025-03-13 | 6 | |  | 行业深度研究：公用事业《从成长到红利，城燃行业价值重构》2025-03-13 | 7 | |  | ...

Investment Rating - The report initiates coverage with a "Buy" rating for WuXi XDC [1][3][4] Core Insights - The global ADC CRDMO market is expanding, with the company benefiting from a growing order pipeline and a dual-factory strategy that enhances capacity and customer retention. The company is also entering the XDC market to create a second growth curve [3][4][5] Summary by Sections Company Overview - WuXi XDC is a leading end-to-end ADC CRDMO provider, benefiting from high industry demand and a growing order book. The projected EPS for 2024-2026 is 0.89, 1.24, and 1.66 CNY respectively, with a target price of 43.4 CNY based on a 35X PE for 2025 [4][16] Market Dynamics - The global ADC drug market is expected to grow to 64.7 billion USD by 2030, with a CAGR of 30% from 2022 to 2030. The outsourcing market for ADC and broader bioconjugates is projected to reach 11 billion USD by 2030, with a CAGR of 28% [4][40] Financial Performance - The company has shown strong revenue growth, with revenues increasing from 311 million CNY in 2021 to an estimated 2.124 billion CNY in 2023, representing a CAGR of 180.7%. The net profit is expected to grow significantly, reaching 1.067 billion CNY in 2024 [8][31] Production Capacity and Strategy - The company is implementing a dual-factory strategy to enhance global production capacity, with new facilities in Singapore expected to be operational by the end of 2025. The company has 18 clinical stage III projects and is advancing its ADC pipeline [5][19][37] Growth Opportunities - The XDC market is emerging, with significant potential in non-oncological indications. The company is strategically positioned to capitalize on this growth by leveraging its existing technology and expanding its project and client base [5][21][22]

Group 1: Utility Industry - The report maintains an "Overweight" rating for the utility sector, particularly focusing on city gas companies transitioning from growth to dividend phases, with expected improvements in free cash flow and dividend payouts [2][24]. - The natural gas consumption volume is projected to grow significantly, with a 5-year CAGR of 12.4%, driven by urbanization and environmental policies [3][24]. - The report highlights the challenges faced by the city gas industry, including slowing gas consumption growth and rising costs, which have led to a decline in return on equity (ROE) and net profit growth [3][25]. Group 2: Kid's King Company - The report maintains an "Overweight" rating for Kid's King, projecting EPS growth of 76%, 65%, and 37% for 2024-2026, with a target price of 19.14 yuan [6][7]. - The establishment of a subsidiary, Smart Future, aims to provide AI-driven solutions for children and new families, enhancing the company's position in the mother and child retail sector [6][7]. - Kid's King is expanding its store network and enhancing its digital capabilities, which are expected to accelerate its AI product deployment and improve customer engagement [6][7]. Group 3: Market Performance - The report notes that the equity market has performed well, with a year-to-date return of 0.59% for risk parity strategies, indicating a positive outlook for equity investments [8][10]. - The report emphasizes the strong historical performance of H-share gas companies, which have benefited from early market entry and the establishment of exclusive operating rights [3][24]. - The report suggests that the overall market sentiment remains optimistic, with expectations for continued growth in the equity market driven by favorable economic conditions [8][10].

Industry Investment Rating - The report assigns a "Leading" investment rating to the pharmaceutical industry, indicating an expectation of attractive performance relative to the benchmark index over the next 12 months [1]. Core Insights - The strong foundation project in healthcare is expected to create new opportunities in the medical device sector, with a focus on innovative drugs, prescription drugs, and CXO during the annual report season [1][4]. - The report highlights the potential benefits of the healthcare strong foundation project, which aims to enhance grassroots medical services and infrastructure, thereby driving growth in the medical device market [4][6]. - The report suggests that the pharmaceutical sector still has significant room for recovery, given the favorable policies expected to be implemented in the second half of 2025, alongside the current low valuations of the sector [4]. Summary by Sections Market Performance - The Hang Seng Index fell by 3.2% during the week of March 6-12, 2025, while the Hang Seng Healthcare Index decreased by 2.8%, ranking 10th among 12 industry indices [4][8]. - Sub-sectors such as biotechnology, life sciences tools and services, and pharmaceuticals experienced declines of 1.1%, 1.3%, and 1.6% respectively [4]. Investment Recommendations - The report recommends focusing on sub-sectors with potential for above-expectation performance, including innovative drugs, prescription drugs, and CXO [4]. - Specific companies highlighted for their growth potential include 康方生物 (CanSino Biologics), 信达生物 (Innovent Biologics), and 传奇生物 (Legend Biotech), which are expected to benefit from short-term catalysts and high growth [4][6]. - The report also emphasizes the importance of AI in healthcare, suggesting investment in companies with clear applications in health management [4]. Company Updates - 康方生物 has completed patient enrollment for its Phase III clinical trial of 卡度尼 (AK104) for high-risk liver cancer [6]. - 云顶新耀 has initiated the first human trial for its mRNA personalized cancer vaccine EVM16 [7]. - 翰森制药 received approval for a new indication for 阿美替尼 (Amehtinib) for non-small cell lung cancer [7]. - 中国生物制药's injection of 甲磺酸艾立布林 has been approved by the FDA for metastatic breast cancer treatment [7]. Valuation Overview - The report provides a valuation summary indicating that the pharmaceutical sector has a TTM P/E ratio of 11.3, while other sectors like life sciences tools and services have a TTM P/E of 7.3 [13].

Investment Rating - The industry investment rating is "Recommended (Maintain)" [1] Core Views - The pharmaceutical sector has shown signs of recovery, with a focus on innovative drugs, the innovative drug industry chain, and AI medical applications as key investment directions [2][3][4] - The pharmaceutical sector outperformed the CSI 300 index, rising by 4.96% from February 5 to February 28, 2025, compared to a 1.91% increase in the CSI 300 index [3][5] - Continuous policy support for innovative drugs has improved the domestic research and payment environment, benefiting differentiated innovative products [8][9] Summary by Sections 1. February 2025 Market Review - The pharmaceutical sector's performance improved compared to 2024, with the Shenwan Pharmaceutical Index rising by 1.1% since the beginning of 2025, while the CSI 300 index fell by 1.1% [6][8] - The sector's recovery is attributed to positive catalysts in AI medical applications and innovative drugs [6] 2. Investment Strategy for March 2025 - The report suggests focusing on segments with good growth potential and industrial logic, emphasizing innovation and internationalization as core themes [12] - AI medical applications are highlighted as an important direction for the pharmaceutical sector in 2025 [12] 3. Recommended Stocks - **BeiGene**: Leading in innovative drugs with strong sales growth and potential for global market expansion [22] - **Hengrui Medicine**: Expected to see rapid growth driven by new product cycles and international expansion [23] - **CanSino Biologics**: Significant potential in the global market with promising clinical results [23] - **WuXi AppTec**: A leading integrated CXO company with strong growth in orders and revenue recovery [24] - **Aibo Medical**: High growth potential in the ophthalmic device sector, benefiting from aging demand [25] - **Tongrentang**: A well-established brand in traditional Chinese medicine with potential for operational improvements [25] 4. Economic Data and Industry Trends - The pharmaceutical manufacturing industry saw a slight decline in revenue and profit in 2024, but expectations for recovery in 2025 are positive [37] - The overall valuation of the pharmaceutical sector is at 25.78 times, with a premium over the CSI 300 index of 116.32% [30]

Group 1: Shizai Bio - Shizai Bio's iPSC-derived cell therapy for ALS has received FDA approval for clinical trials, marking it as the first globally and the first from China to gain Orphan Drug Designation [2] Group 2: Burning Stone Medical - Burning Stone Medical has partnered with BGI Genomics to enhance global tumor precision diagnosis, leveraging BGI's sequencing technology and Burning Stone's extensive product portfolio [3][4] Group 3: Jingtai Technology - Jingtai Technology and Guangdong Hengjian Investment announced a project in the Greater Bay Area to develop AI infrastructure, aiming to drive a billion-level AI pharmaceutical materials industry [5][6] Group 4: Tongxin Medical - Tongxin Medical's BrioVAD system has completed its first clinical enrollment in the US, entering a multi-center clinical trial for advanced heart failure [7][8] Group 5: WuXi XDC - WuXi XDC and LigaChem have deepened their collaboration in ADC development, aiming to accelerate the transition of ADC candidates from early research to commercialization [9][10] Group 6: Huayi Lekang - Huayi Lekang's GS1191-0445 injection has entered Phase III clinical trials, marking it as China's first gene therapy for Hemophilia A [12][13] Group 7: Ruike Bio - Ruike Bio's new adjuvanted nine-valent HPV vaccine REC604c has had its clinical trial application accepted, targeting the male market and reducing the required doses from three to two [15] Group 8: Angkuo Pharmaceutical - Angkuo Pharmaceutical's CUSP06 has received FDA Fast Track designation for treating platinum-resistant ovarian cancer, showing promising early clinical results [16] Group 9: Phanes Therapeutics - Phanes Therapeutics has completed the first patient dosing of its dual antibody drug PT217 in combination with chemotherapy for small cell lung cancer [18] Group 10: Jiayue Pharmaceutical - Jiayue Pharmaceutical's JYP0015 has received clinical trial approval for treating RAS-mutant cancers, showing significant efficacy compared to similar drugs [20][22]

Financial Performance - Revenue for the six months ended June 30, 2024, increased by 67.6% to RMB 1,665.2 million compared to RMB 993.5 million in the same period of 2023[7]. - Gross profit rose by 133.4% to RMB 535.3 million, with a gross margin of 32.1%, up from 23.1% in the previous year[7]. - Net profit attributable to the company's owners surged by 175.5% to RMB 488.2 million, with a net profit margin of 29.3%, compared to 17.8% in the prior year[7]. - Adjusted net profit attributable to the company's owners increased by 146.6% to RMB 533.6 million, with an adjusted net profit margin of 32.0%, up from 21.8%[7]. - Revenue for the six months ended June 30, 2024, increased by 67.6% year-on-year to RMB 1,665.2 million[12]. - Gross profit for the same period rose by 133.4% year-on-year to RMB 535.3 million[12]. - Net profit attributable to the company's owners increased by 175.5% year-on-year to RMB 488.2 million[12]. - Adjusted net profit for the six months ended June 30, 2024, grew by 146.6% year-on-year to RMB 533.6 million[12]. - The company recorded a net other income of RMB 40.4 million for the six months ended June 30, 2024, primarily due to foreign exchange gains[60]. - The company reported a total comprehensive income of RMB 488,788 thousand for the six months ended June 30, 2024[124]. Operational Growth - The total number of new signed comprehensive projects increased from 17 as of June 30, 2023, to 26 as of June 30, 2024[12]. - Ongoing IND post-projects rose from 43 as of June 30, 2023, to 76 as of June 30, 2024[12]. - The total number of ongoing comprehensive projects increased from 110 as of June 30, 2023, to 167 as of June 30, 2024[12]. - The total number of drug discovery projects executed since inception increased from 350 as of June 30, 2023, to 538 as of June 30, 2024[13]. - The company expanded its workforce to 1,496 full-time employees as of June 30, 2024, a 72.2% increase year-on-year[12]. - The company has increased its drug discovery projects to a total of 538, up from 350 as of June 30, 2023, representing a growth of 54%[19]. - As of June 30, 2024, the company has 138 preclinical and phase I process development projects, an increase of 44 projects from 94 on June 30, 2023, marking a growth of 47%[20]. - The company has expanded its late-stage development and process validation projects to 29, up from 16 as of June 30, 2023, which is an 81% increase[21]. Strategic Initiatives - The company is a leading CRDMO focused on the global ADC and broader bioconjugate drug market, ranked as the second largest in the world based on 2022 revenue[10]. - The company aims to enhance its platform and drive the development of the bioconjugate drug industry, benefiting global biopharmaceutical partners and patients[10]. - The strategy of "Empower, Follow, and Win Molecules" is employed to meet the needs of clients and partners in developing bioconjugate drugs[10]. - Winning clients in the CMC stage is identified as a key growth driver for the company's future[10]. - The company is constructing a new production line in Wuxi, expected to start operations in Q4 2024, enhancing its capacity for mAb intermediates and bioconjugate drug substance and drug product[23]. - The new facility in Singapore is on track to begin GMP-compliant operations by the end of 2025 or early 2026, with plans for four production lines[24]. - The company is expanding its production capabilities for conjugated antibodies in Wuxi and building new facilities in Singapore to meet increasing demand[22]. Market Position and Demand - The global ADC drug market is projected to grow from USD 7.9 billion in 2022 to USD 64.7 billion by 2030, with a compound annual growth rate (CAGR) of 30.0%[39]. - Revenue from North America increased to RMB 823.2 million, accounting for 49.4% of total revenue, up from 37.0% in the previous period[47]. - Revenue from Europe rose to RMB 310.2 million, representing 18.7% of total revenue, compared to 23.1% previously[47]. - The number of customers grew significantly from 169 to 309 within a six-month period, indicating strong market demand[1]. - 13 out of the top 20 global pharmaceutical companies are collaborating with the company on ADC or XDC projects, contributing to 28.9% of total revenue[1]. Financial Management - The company has achieved a 100% delivery success rate from its expanded production facility in Wuxi, contributing to a robust supply chain[23]. - The company aims to reduce greenhouse gas emissions intensity by 50% by 2030, based on 2021 levels[36]. - The company plans to establish a series of forward contracts to manage currency risk associated with foreign currency transactions[80]. - The company is adopting hedge accounting for derivatives to mitigate the impact of foreign exchange rate fluctuations on profit and loss[80]. - The company reported a significant increase in share-based compensation expenses, rising to RMB 45,391,000 in the first half of 2024 from RMB 31,780,000 in 2023[82]. Corporate Governance and Compliance - The audit committee and independent auditor confirmed that the interim results and report comply with applicable accounting standards, laws, and regulations[89]. - The board is responsible for assessing and determining the nature and extent of risks the group is willing to take to achieve strategic objectives, maintaining effective risk management and internal control systems[90]. - The company has implemented anti-bribery and anti-corruption policies, strictly prohibiting any improper payments by employees or representatives[90]. - The compliance office has established a reporting mechanism to handle complaints against directors, senior management, employees, customers, and other business partners[91]. - The board confirmed that there were no changes in director information that needed to be disclosed as of June 30, 2024[87]. Shareholder Information - As of June 30, 2024, the company has issued a total of 1,198,215,456 shares[96]. - Dr. Li Jun Cai holds 32,455,840 shares, representing approximately 2.71% of the company's issued share capital[95]. - WuXi Biologics held 600,000,000 shares, representing 50.07% of the total issued shares as of June 30, 2024[98]. - The company has granted stock options with a total of 77,023,246 shares, of which 610,956 have been exercised and 1,045,438 have been canceled[105]. - The company has a total of 44,863,246 shares granted at an exercise price of RMB 1.868 on January 6, 2023, with 832,610 shares exercised[105]. Future Outlook - The company plans to continue expanding its CRDMO services, focusing on bioconjugates and monoclonal antibodies[127]. - The company is actively investing in new product development, with a focus on expanding its ADC capabilities through XDC technology[193]. - WuXi Biologics is exploring market expansion opportunities in regions such as Europe and Asia, aiming for a C% increase in market share by 2025[193]. - The company announced plans for strategic acquisitions to enhance its service offerings and technological capabilities, targeting D potential companies in the biotech sector[193].

（於開曼群島註冊成立的有限公司） （股份代號：2268） 截 至2024年6月30日 止 六 個 月 之 中 期 業 績 公 告 | 財 | 務 | 摘 | 要 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | | | | | | 截 | | 至6月30日 | | 止 六 | 個 | 月 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ...